Eloxx Pharmaceuticals, Inc. Human Resources Contracts & Agreements
30 Contracts & Agreements
- Bonus & Incentive Agreements (8 contracts)
- Change of Control Agreements (1)
- Confidentiality Agreements (2)
- Consulting Agreements (1)
- Employment Agreements (12)
- Retention Agreements (5)
- Separation Agreements (1)
- Employment offer letter between Eloxx Pharmaceuticals, Inc. and Gary D Rakers dated March 26, 2021 (Filed With SEC on May 7, 2021)
- Employment Agreement, dated as of April 1, 2021, by and between Sumit Aggarwal and Eloxx Pharmaceuticals, Inc (Filed With SEC on April 1, 2021)
- Employment Agreement, dated as of April 1, 2021, by and between Vijay Modur and Eloxx Pharmaceuticals, Inc (Filed With SEC on April 1, 2021)
- Separation Agreement and General Release, dated as of April 1, 2021, by and between Gregory C. Williams and Eloxx Pharmaceuticals, Inc (Filed With SEC on April 1, 2021)
- Executive Employment Agreement between Eloxx Pharmaceuticals, Inc. and Gregory C. Williams dated as of February 25, 2020 (Filed With SEC on March 6, 2020)
- Executive Employment Agreement between Eloxx Pharmaceuticals, Inc. and Neil Belloff dated as of February 25, 2020 (Filed With SEC on March 6, 2020)
- Employment offer letter between Eloxx Pharmaceuticals, Inc. and Stephen G. MacDonald dated as of September 24, 2019 (Filed With SEC on March 6, 2020)
- Change in Control Severance Benefit Plan (Filed With SEC on November 6, 2019)
- Executive Employment Agreement between Eloxx Pharmaceuticals, Inc. and David Snow dated as of June 18, 2018 (Filed With SEC on March 14, 2019)
- Employment Agreement with Dr. Greg Williams dated June 25, 2018 (Filed With SEC on June 26, 2018)
- Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)
- Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)
- Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)
- Form of Israeli Stock Option Grant Package under the Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)
- Employment Agreement, dated as of March 12, 2018, between Eloxx Pharmaceuticals Inc. and Gregory Weaver (Filed With SEC on March 16, 2018)
- Employment Agreement, dated as of March 12, 2018, between Eloxx Pharmaceuticals Inc. and Pedro Huertas (Filed With SEC on March 16, 2018)
- Performance Stock Option Grant Notice and Stock Option Agreement (Inducement Grant) between Eloxx Pharmaceuticals, Inc. and Robert E. Ward, dated March 5, 2018 (Filed With SEC on March 16, 2018)
- Performance Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (Inducement Grant) between Eloxx Pharmaceuticals, Inc. and Robert E. Ward, dated March 5, 2018 (Filed With SEC on March 16, 2018)
- Employment Agreement, dated as of December 26, 2017, between Eloxx Pharmaceuticals, Inc. and Robert E. Ward (Filed With SEC on December 27, 2017)
- Consulting Agreement, dated December 1, 2014, by and between Eloxx Pharmaceuticals Ltd. and Dr. Silvia Noiman (Filed With SEC on December 22, 2017)
- RETENTION AGREEMENT (Filed With SEC on February 17, 2015)
- RETENTION AGREEMENT (Filed With SEC on February 17, 2015)
- RETENTION AGREEMENT (Filed With SEC on December 3, 2014)
- EMPLOYMENT AGREEMENT (Filed With SEC on June 27, 2014)
- RETENTION AGREEMENT (Filed With SEC on May 19, 2014)
- SENESCO TECHNOLOGIES, INC. 2008 INCENTIVE COMPENSATION PLAN (As Amended and Restated February 11,2014) ARTICLE ONE GENERAL PROVISIONS (Filed With SEC on May 9, 2014)
- Senesco Technologies, Inc. Retention Policy for Officers12 (Adopted by the Board on [____]) (Filed With SEC on October 15, 2012)
- SENESCOTECHNOLOGIES, INC. 2008 INCENTIVE COMPENSATIONPLAN (AsAmended and Restated May 25, 2010) ARTICLEONE GENERALPROVISIONS (Filed With SEC on May 28, 2010)
- ConfidentialTreatment has been requested for portions of this exhibit. The copy filedherewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on November 14, 2007)
- Confidential Treatment has been requested forportions of this exhibit. The copy filed herewith omits the information subjectto the confidentiality request. Omissions are... (Filed With SEC on November 14, 2007)
